Secondary Hyperparathyroidism Due to Chronic Kidney Disease
This patient has secondary hyperparathyroidism caused by chronic kidney disease, not primary hyperparathyroidism—the combination of elevated PTH (173 pg/mL) with hypocalcemia (7.9 mg/dL) is pathognomonic for renal-driven parathyroid stimulation. 1, 2
Why This Is Secondary, Not Primary Hyperparathyroidism
Primary hyperparathyroidism is defined by hypercalcemia (>10.2 mg/dL) with elevated or inappropriately normal PTH 3. Your patient has the opposite biochemical picture: hypocalcemia with elevated PTH is the hallmark of secondary hyperparathyroidism 1, 2. In CKD, reduced 1,25-dihydroxyvitamin D production leads to decreased intestinal calcium absorption and impaired PTH suppression, driving compensatory PTH elevation 2.
Immediate Diagnostic Priorities
Before initiating any treatment, you must:
1. Assess Symptom Severity
- Check for paresthesias, Chvostek's sign, Trousseau's sign, bronchospasm, laryngospasm, tetany, or seizures—these indicate severe symptomatic hypocalcemia requiring urgent IV calcium 1
- Measure ionized calcium to confirm true hypocalcemia, as total calcium can be misleading if albumin is abnormal 1
2. Determine CKD Stage
- Measure serum creatinine and calculate eGFR immediately 1, 2
- PTH begins rising when GFR falls below 60 mL/min/1.73 m² 2
- The target PTH range depends entirely on CKD stage: 35–70 pg/mL for Stage 3,70–110 pg/mL for Stage 4, and 150–300 pg/mL for Stage 5/dialysis 2
3. Measure Serum Phosphorus
- Elevated phosphorus drives PTH secretion and is expected as renal function declines 1, 2
- You cannot start active vitamin D therapy if phosphorus >4.6 mg/dL because this worsens vascular calcification and increases the calcium-phosphate product 2
4. Check 25-Hydroxyvitamin D
- 47–76% of CKD Stage 3–4 patients have 25(OH)D <30 ng/mL, which aggravates secondary hyperparathyroidism 2
- Nutritional vitamin D deficiency must be corrected first with ergocalciferol or cholecalciferol 2
Initial Management Algorithm
If Symptomatic Hypocalcemia (Tetany, Seizures, Positive Chvostek/Trousseau)
- Start IV calcium gluconate infusion at 1–2 mg elemental calcium per kg per hour 1, 4
- Monitor ionized calcium every 4–6 hours 1
If Asymptomatic Hypocalcemia
Start oral calcium carbonate 1–2 g elemental calcium three times daily with meals 1, 2
Replete nutritional vitamin D if 25(OH)D <30 ng/mL
Control hyperphosphatemia before starting active vitamin D
Initiate active vitamin D (calcitriol) only after:
Dosing: Start calcitriol 0.25–0.5 μg daily 1, 5 or 0.5–1.0 μg 2–3 times weekly 2
Critical Monitoring Schedule
- Calcium and phosphorus: Every 2 weeks for the first month after starting calcitriol, then monthly for 3 months, then every 3 months 1, 2
- PTH: Monthly for the first 3 months, then every 3 months once target range is achieved 1, 2
- If calcium rises >10.2 mg/dL: Immediately discontinue all vitamin D therapy 1, 2
Common Pitfalls to Avoid
Never target normal PTH levels (<65 pg/mL) in dialysis patients—this causes adynamic bone disease with a four-fold increase in fracture risk 2. The appropriate target for Stage 5 CKD is 150–300 pg/mL 2.
Never start calcitriol with uncontrolled hyperphosphatemia—this dramatically worsens vascular calcification and increases the calcium-phosphate product, which should never exceed 70 mg²/dL² 2.
Do not use calcitriol or active vitamin D analogs in primary hyperparathyroidism—they increase intestinal calcium absorption and exacerbate hypercalcemia 3. This patient does not have primary hyperparathyroidism.
Avoid PTHrP measurement—it has no role in evaluating secondary hyperparathyroidism and should be reserved for malignancy-associated hypercalcemia with suppressed PTH 2.
When to Consider Parathyroidectomy
Surgical referral is indicated only if 2:
- PTH remains persistently >800 pg/mL despite optimized medical therapy
- Hypercalcemia and/or hyperphosphatemia are refractory to treatment
- Reassess after 3–6 months of optimized medical therapy before proceeding